Abstract The outcome of Multiple Myeloma (MM) patients has dramatically improved,
however, most patients will still succumb to their disease. Additional therapeutic options are
urgently needed and novel immunotherapies are enormously promising in the therapeutic
armamentarium against MM. The first step in the development of any immunotherapy needs
to be the identification of an appropriate target structure. In this review we present the current
knowledge on surface molecule CD229, a member of the Signaling Lymphocyte Activation …